located near the telomere of the chromosome 4 short arm (7) (8) (9) . The HD mutation, discovered in 1993, occurs in the first exon of a 67-exon gene encoding a large novel protein (10) (11) (12) . All HD patients have an expansion in a sequence of consecutive CAG codons that lengthens the stretch from the 10 to 34 repeat units seen on normal chromosomes to more than 36 repeat units. The major outstanding question since discovery of the HD gene is, how does the expanded CAG repeat cause specific neuronal loss? Delineation of similar CAG expansion mutations in a number of other neurodegenerative disorders suggests that the eventual answer may reveal a common mechanism of neuronal toxicity mediated by the mutant gene products.
GENOTYPE:PHENOTYPE CORRELATIONS
Once a disease gene has been identified, the pursuit of genotype:phenotype correlations can represent a fruitful approach for gaining insight into pathogenesis. In most disorders, this approach involves comparison of the phenotypic effects of different mutations in the same gene. However, numerous studies have established that the HD CAG repeat expansion is the sole mutation responsible for all bona fide inherited and sporadic cases of HD . Thus, in HD, the "genotype" is an assessment of the number of CAG repeat units in the person's HD allele, whereas the "phenotype" can represent any of a number of descriptive clinical parameters, such as neuro-logic symptoms, psychiatric symptoms, cognitive symptoms, age at onset, age at death, rate of disease progression, degree of neuropathology, etc.
To date, the relationship between the size of the CAG repeat and the age at onset of neurologic symptoms has been examined in numerous data sets (43) . Most HD cases show adult onset and are associated with CAG allele lengths of 40 to 50 units. Disease alleles with CAG expansion in the 35 to 40 unit range may show very late onset or, in some cases, may be nonpenetrant. By contrast, individuals with more than 60 CAG units typically show onset of HD in their juvenile years. All of these studies report an inverse correlation between CAG repeat length and age at onset of neurologic symptoms. However, there is considerable variation in the age at onset associated with any given CAG repeat length ( Fig. 1) , suggesting that it can be modified by environmental, genetic, or stochastic modifiers. These effects can be minimized by considering the mean age at neurologic onset associated with any repeat length. By combining a number of published data sets (Fig. 1 genic process is first triggered with no prior evidence of dysfunction. Not surprisingly, GAG repeat length has also been inversely correlated with the age of onset of psychiatric manifestations in HD (13) . A similar relationship with age at death (Fig. 2) indicates that the presence of an HD-length GAG repeat produces a reduced lifespan (13). However, despite an apparent increased rate of neuronal loss with increasing GAG repeat lengths, the length of time from onset of neurologic symptoms to death does not show a corresponding relationship. Indeed, the duration of disease from neurologic onset to death is remarkably similar (-15 years) for different repeat lengths (Fig. 2) . Thus, progression to death is not highly correlated with the size of the mutant allele, as is neurologic onset, and it probably involves additional factors beyond degree of neuronal loss. Indeed, direct attempts to relate the patient's overall functional (71) . The genetically distinct SCA7, causing spinocerebellar ataxia with retinal degeneration, also shows evidence of expanded CAG in genomic DNA and of lengthened polyglutamine in a 130-kD nuclear protein, but the locus has not yet been cloned (72, 73) .
As Fig. 3 shows for several of these disorders, a relationship exists between CAG repeat length and age at onset that is comparable to the pattern seen in HD. The age at onset data for SCAI superimpose on the HD curve whereas data for DRPLA and SCA3/MJD are displaced to the right and those for SCA2 are displaced to the left. These findings indicate that in each disorder the degree of CAG expansion necessary to cause a detectable neurologic deficit differs. The slopes of the latter three curves also differ from HD and SCA1, indicating a greater effect of each additional CAG unit on reducing age at onset. These comparisons suggest that in each disorder, the deleterious effects of the expanded CAG act in a similar manner but on target cell populations and with a CAG length dependence that are dictated by the context in which the mutation is expressed. If the model of gradual neuronal decline to a symptomatic onset threshold is correct, individual differences in the curves would reflect corresponding differences in the threshold for different neuronal cell types and for the contextdependent effect of each embedded CAG repeat on the rate of neuronal decline. In the more severe young-onset cases, the neuronal pathology extends beyond the regions most characteristic of each disorder to parts of the brain that degenerate in one or more of the other CAG repeat disorders. This suggests that each CAG repeat might produce progressive neuronal loss 60  50  40  30  20   10  70  60  50  40  30  20  10  70  60  50  40  30  20  10  70  60  50  40  30  20  10  70  60  50  40  30  20  10  0  40  60  80  100  120 Number of CAG Repeat Units (78) (79) (80) (81) , 1226 HD cases (circles) (10,13,21,23-26,28 -31,34,36,37,42, 75-77) , 149 DRPLA cases (squares) (58, (82) (83) (84) and 332 MJD/SCA3 cases (triangles) (64, 68, 69, (85) (86) (87) of more than one neuronal cell population, but with a different rate of decline in each population. A notable feature of these disorders is the age-at-onset phenotype for individuals homozygous for the disease allele (Fig. 3) . In HD, SCAI, and SCA2, a second dose of the disease allele does not aggravate the disease process, as the age at onset observed matches well that expected on the basis of the disease allele with the larger repeat. By contrast, in both DRPLA and SCA3/ MJD individuals, the combined effects of two disease alleles produces an age of onset earlier than that predicted based on either allele alone. The lack of a significant effect of a second disease allele in HD, SCAI, and SCA2, suggests that the presence of a single mutant gene in these disorders produces sufficient product to maximize the rate of neuronal loss that can be caused by a given length of CAG repeat. On the other hand, in DRPLA and MJD/SCA3, the pathogenic triggering mechanism is not saturated in typical heterozygotes as some capacity to accelerate the process with a second disease allele remains.
MECHANISM OF PATHOGENESIS
Although it is conceivable that the biochemical mechanisms producing neuronal loss in the CAG repeat disorders could differ in each case, the remarkable similarities argue strongly that the pathogenic mechanisms in HD and in the other CAG repeat disorders are closely related. Consequently, defining the pathogenic mechanism in any one of the disorders will probably lead to an understanding of the others and to a delineation of the factors that determine the surprising specificity of neuronal loss. In each case, cell death could either occur as an effect of the long CAG segment in the disease gene mRNA or be due to an expanded polyglutamine segment in the corresponding protein. As each of the genes is unrelated to the others, loss of normal protein function is probably not the primary cause of pathogenesis, although it could certainly contribute to aspects of the disease phenotype (74) . Differences in the capacity of the altered gene products in each disorder to trigger the disease process may depend on many factors including their concentration, localization, normal function, and constraints imposed by product structure outside the CAG/polyglutamine region. Hopefully, the ability to compare specific neuronal loss in a number of disorders will accelerate recognition of the steps in pathogenesis that are shared between them, providing the knowledge to develop rational treatments.
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